New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
09:05 EDTORCL, ITMN, ACAD, TUMI, GES, MOV, PERY, AZN, YHOO, CSCO, SCHLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Perry Ellis (PERY), up 5.2%... Movado (MOV), up 2.4%... ALSO HIGHER: InterMune (ITMN), up 12.2% after health technology appraisal body in England and Wales recommends use of its Esbriet drug... ACADIA (ACAD), up 7.5% after presenting detailed results from a Phase III study of its treatment for Parkinson's disease psychosis... AstraZeneca (AZN), up 2.8% after saying it plans to restructure its SG&A activities to cut out about 2,300 jobs, announcing partnership agreement with Moderna Therapeutics... Yahoo! (YHOO), up 2% following upgrade at Oppenheimer... DOWN AFTER EARNINGS: Oracle (ORCL), down 7.6%... Guess (GES), down 6%... Tumi (TUMI), down 6%... Scholastic (SCHL), down 11.5%... ALSO LOWER: Cisco (CSCO), down 2.5%, following downgrade at FBR Capital... General Moly (GMO), down 21%, after work suspended on a $665M loan being negotiated for the development of its Mt. Hope Project.
News For ORCL;CSCO;YHOO;AZN;PERY;MOV;GES;TUMI;ACAD;ITMN;SCHL From The Last 14 Days
Check below for free stories on ORCL;CSCO;YHOO;AZN;PERY;MOV;GES;TUMI;ACAD;ITMN;SCHL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 13, 2014
10:43 EDTCSCOOptions with increasing implied volatility
Options with increasing implied volatility: PSEC CSCO XONE NDLS
09:31 EDTPERYPerry Ellis downgraded to Neutral from Buy at Sidoti
09:15 EDTYHOOOn The Fly: Pre-market Movers
Subscribe for More Information
08:31 EDTAZNAstraZeneca says Phase 3 trials of lesinurad for gout met primary endpoints
AstraZeneca announced top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor, as a combination therapy for the treatment of patients with symptomatic gout. Lesinurad is an investigational agent that inhibits the URAT1 transporter, increasing uric acid excretion and thereby lowering serum uric acid. In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in combination with allopurinol met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0mg/dL at month 6 compared to allopurinol alone. In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the primary endpoint, with a statistically significant higher proportion of patients reaching the target sUA goal of <5.0mg/dL at month 6 compared to febuxostat alone. Although lesinurad 200mg did not achieve statistical significance at month 6, this dose in combination with febuxostat, was superior to placebo plus febuxostat at all other time points. Results from these Phase III clinical trials will be submitted to a scientific meeting later in 2014. The company is proceeding with preparation of regulatory submissions for lesinurad 200mg combination therapy.
07:22 EDTCSCOGoldman pushes Cisco head to step-up software, Bloomberg says
Subscribe for More Information
August 12, 2014
17:09 EDTYHOOYahoo says Alibaba to sell assets relating to its SME loan business for $518M
Subscribe for More Information
16:50 EDTYHOOAlibaba restructures arrangement with Small and Micro Financial Services Company
Subscribe for More Information
15:03 EDTCSCOArista Networks faces rougher road ahead, WSJ says
Arista Networks (ANET) shares have been strong since the company's IPO and its growth prospects make a "good case for a decent premium," but the current valuation gap compared to its peers "seems wide", according to The Wall Street Journal's "Heard on the Street" column, which noted that Cisco (CSCO) has the resources and incentive to push back against Arista's attempts to take share in network switches. Reference Link
13:05 EDTYHOOYahoo acquires Zofari, terms not disclosed
Subscribe for More Information
13:04 EDTCSCOCisco technical comments before earnings
In the last three months the stock has outperformed the broader averages, rising by nearly 9%. The trend in that time has been up, but with the bulk of gains having been realized near the start of the period. There was one larger bump up in price that was corrected, but that high at $26.08 now becomes an objective for bulls to take out on the upside on good news. The reason for this is that the $26 to $26.50 area forms a big double top when viewed on a 2-year daily chart. The bulls need to break this area of resistance for the stock to become long-term bullish. If they can manage that, next resistance above $26.50 would be at $27.74. If the news disappoints, that potentially bearish double top pattern could asset itself. The $23.50 area on a break lower would be the first test. The middle of the "M" pattern would be at $21.27.
12:49 EDTCSCOCisco August 25 straddle priced for 4.7% move into Q4
Subscribe for More Information
07:42 EDTCSCOCisco August volatility increases into Q4 and outlook
Subscribe for More Information
06:06 EDTCSCOCisco planning to fire 300 employees in Israel, Globes reports
As part of a worldwide streamlining effort, Cisco is planning to fire 300 employees in Israel, Globes reports. Reference Link
05:58 EDTAZNStocks with implied volatility movement; P AZN
Subscribe for More Information
August 11, 2014
15:23 EDTITMNInterMune rumored to be working with adviser to explore options, Betaville says
Subscribe for More Information
15:22 EDTITMNInterMune August volatility increases on wide price movement
Subscribe for More Information
05:55 EDTCSCOCisco expected to report solid Q4 results at Wells Fargo
Subscribe for More Information
August 9, 2014
16:26 EDTORCLOracle sues Oregon over dispute with state's health-insurance exchange, WSJ says
Subscribe for More Information
August 8, 2014
08:31 EDTCSCOMorgan Stanley expects Cisco to report good results, conservative outlook
Morgan Stanley expects Cisco to report results of 54c/$12.26B vs. consensus of 53c/$12.14B and said checks indicate the enterprise market is improving. The firm expects Cisco's outlook to be conservative and said concerns over rapid software-defined networking adoption and margin impact are overblown. Shares are Overweight rated with a $30 price target.
06:01 EDTYHOOYahoo to strengthen email encryption for users, Mashable reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use